期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 14, 期 10, 页码 1115-1125出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2014.957188
关键词
chemoradiotherapy; chemotherapy; clinical trials; genomics; pancreas cancer
类别
资金
- Cancer Research UK [16057, 18521] Funding Source: researchfish
- National Institute for Health Research [ACF-2014-14-009] Funding Source: researchfish
Treatment of metastatic and locally advanced pancreatic cancer has made slow progress during the last decade. Single agent gemcitabine or in combination with capecitabine or erlotinib remained the preferred systemic treatment options until 2010 when the ACCORD study demonstrated significantly improved outcomes achieved with FOFIRINOX compared with gemcitabine monotherapy. Since 2010, use of FOLFIRINOX has increased both in metastatic and locally advanced cancer. Despite its gaining popularity among oncologists, unanswered questions remain. Do the often necessary dose modifications affect its efficacy? Are the toxicities manageable and how applicable are the results of the ACCORD study in the general population of patients with newly diagnosed pancreatic cancer? In the present manuscript, we review the published literature regarding the use of FOLFIRINOX, the challenges associated with its use and how it will be optimally incorporated into the management of patients with different stages of pancreatic cancer and ultimately, in a more biomarker-driven pathway algorithm.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据